| CUSTOMER |
CUSTOMER |
92%
|
For the three months ended March 31, 2026 , three customers accounted for 99 % of revenue under supply agreements |
| ALFRESA |
ALFRESA |
90%
|
we will supply Alfresa's requirements (and Alfresa will purchase from ARS its requirements) for a transfer price in the low-double-digit percentage on net sales of neffy in Japan |
| ALK-U-S |
ALK-U-S |
90%
|
we granted ALK U.S. a non-exclusive, royalty-free license to use the neffy trademarks and copyrights and the ARS house marks in the U.S. solely in connection with promoting neffy |
| PEDIATRIX-THERAPEUTICS |
PEDIATRIX-THERAPEUTICS |
80%
|
In March 2021, we entered into a collaboration and distribution agreement (the “Pediatrix Agreement”) with Pediatrix Therapeutics (“Pediatrix”). |
| AMRX |
Amneal Pharmaceuticals, Inc. |
72%
|
. We believe that NARCAN’s widespread use clearly demonstrates market uptake in response to the advantages of an intranasal product via proven device over injection, considering in particular that NA… |
| AMRX |
Amneal Pharmaceuticals, Inc. |
72%
|
Reciprocal relationship from AMRX graph: Reciprocal relationship from SPRY graph: Reciprocal relationship from AMRX graph: Reciprocal relationship from SPRY graph: . We believe that NARCAN’s widespre… |
| AQST |
Aquestive Therapeutics, Inc. |
72%
|
Reciprocal relationship from AQST graph: Reciprocal relationship from SPRY graph: Reciprocal relationship from AQST graph: Reciprocal relationship from SPRY graph: Reciprocal relationship from AQST g… |
| AQST |
Aquestive Therapeutics, Inc. |
72%
|
higher dose spray candidates including Bryn Pharma, Hikma Pharmaceuticals, Inc. (previously INSYS Therapeutics, Inc.), Nasus Pharma Ltd., Orexo AB, Insignis Therapeutics, Inc. and Belhaven BioPharma.… |
| NSRX |
Nasus Pharma Ltd. |
72%
|
Reciprocal relationship from NSRX graph: Reciprocal relationship from SPRY graph: higher dose spray candidates including Bryn Pharma, Hikma Pharmaceuticals, Inc. (previously INSYS Therapeutics, Inc.)… |
| NSRX |
Nasus Pharma Ltd. |
72%
|
higher dose spray candidates including Bryn Pharma, Hikma Pharmaceuticals, Inc. (previously INSYS Therapeutics, Inc.), Nasus Pharma Ltd., Orexo AB, Insignis Therapeutics, Inc. and Belhaven BioPharma.… |
| ORANY |
ORANY |
72%
|
Reciprocal relationship from ORANY graph: Reciprocal relationship from SPRY graph: tory concern. We may terminate the ALK Agreement in the event ALK makes certain challenges to certain of our patents… |
| ORANY |
ORANY |
72%
|
tory concern. We may terminate the ALK Agreement in the event ALK makes certain challenges to certain of our patents. Prior to a change of control and outside of a set period of time after which we c… |
| AEGIS-THERAPEUTICS-LLC |
AEGIS-THERAPEUTICS-LLC |
62%
|
onths. Epinephrine injectable products have a reported shelf-life range from the date of product manufacture of 18 to 24 months, with a volume-weighted average shelf-life of approximately 22 to 23 mo… |
| ALFRESA-PHARMA-CORPORATION |
ALFRESA-PHARMA-CORPORATION |
62%
|
y products to be offered by sales personnel, which may put us at a competitive disadvantage relative to companies that have more extensive product lines; and • unforeseen delays, costs and expenses a… |
| BELHAVEN-BIOPHARMA-AQUESTIVE-THERAPEUTICS-INC |
BELHAVEN-BIOPHARMA-AQUESTIVE-THERAPEUTICS-INC |
62%
|
higher dose spray candidates including Bryn Pharma, Hikma Pharmaceuticals, Inc. (previously INSYS Therapeutics, Inc.), Nasus Pharma Ltd., Orexo AB, Insignis Therapeutics, Inc. and Belhaven BioPharma.… |
| BRYN-PHARMA-HIKMA-PHARMACEUTICALS-INC |
BRYN-PHARMA-HIKMA-PHARMACEUTICALS-INC |
62%
|
higher dose spray candidates including Bryn Pharma, Hikma Pharmaceuticals, Inc. (previously INSYS Therapeutics, Inc.), Nasus Pharma Ltd., Orexo AB, Insignis Therapeutics, Inc. and Belhaven BioPharma.… |
| COORDINATION-GROUP |
COORDINATION-GROUP |
62%
|
ivacy and security of personal information, including health-related information in certain circumstances, some of which are more stringent than HIPAA and many of which differ from each other in sign… |
| OMERS-ADMINISTRATION-CORPORATION |
OMERS-ADMINISTRATION-CORPORATION |
62%
|
“Credit Agreement”) with RA Capital Agency Services, LLC (as the “Administrative Agent”) and affiliates of OMERS Administration Corporation and RA Capital Management, L.P. as lenders (the “Lenders”),… |
| OREXO-AB-INSIGNIS-THERAPEUTICS-INC |
OREXO-AB-INSIGNIS-THERAPEUTICS-INC |
62%
|
higher dose spray candidates including Bryn Pharma, Hikma Pharmaceuticals, Inc. (previously INSYS Therapeutics, Inc.), Nasus Pharma Ltd., Orexo AB, Insignis Therapeutics, Inc. and Belhaven BioPharma.… |
| PEDIATRIX-THERAPEUTICS-INC |
PEDIATRIX-THERAPEUTICS-INC |
62%
|
y products to be offered by sales personnel, which may put us at a competitive disadvantage relative to companies that have more extensive product lines; and • unforeseen delays, costs and expenses a… |
| RECORDATI-IRELAND-LTD |
RECORDATI-IRELAND-LTD |
62%
|
9.0 million as of December 31, 2025. We are also required to make royalty payments to OrbiMed based on a mid-single-digit percentage of net product sales. Future royalty payment amounts are indetermi… |
| SEQIRUS-PTY-LTD |
SEQIRUS-PTY-LTD |
62%
|
onal clinical studies required for approval of neffy in Japan. The Alfresa Agreement will continue until the later of (i) expiration of the last-to-expire valid claim of our patents or joint patent w… |
| SILVERBACK-THERAPEUTICS-INC |
SILVERBACK-THERAPEUTICS-INC |
62%
|
. Segment Information The Company reports segment information using the management approach and views its operations and manages its business as a single operating segment. The Company’s Chief Operat… |
